| Literature DB >> 28511708 |
Rupak Thapa1, Chintan Bhagat2, Pragya Shrestha1, Suvash Awal1, Pravin Dudhagara3.
Abstract
BACKGROUND: Silver nanoparticles (AgNPs) are believed to be emerging tool against various infectious diseases including multi-drug resistant (MDR) bacteria. In the present study, in vitro synthesis of AgNPs was optimized using 1:50 ratio of macerozyme (25 μg/μl) and 1 mM AgNO3 incubated at 80 °C for 8 h. AgNPs were characterized by UV-Visible spectroscopy, dynamic light scattering (DLS), scanning electron microscopy, energy-dispersive X-ray spectroscopy, transmission electron microscopy (TEM) and X-ray diffraction (XRD).Entities:
Keywords: Antimicrobial activity; Multi-drug resistant (MDR); Silver nanoparticles (AgNPs); Surgical thread
Mesh:
Substances:
Year: 2017 PMID: 28511708 PMCID: PMC5434635 DOI: 10.1186/s12941-017-0216-y
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Fig. 1Size distribution measurement of colloidal AgNPs by DLS
Fig. 2Scanning electron micrographs (SEM) of AgNPs and elemental profiling using EDX. Satellite table indicates the mass composition of elements
Fig. 3Confirmation of elliptical shape of AgNPs by TEM a in fresh and b 1-year-old colloidal sample
Fig. 4XRD pattern of AgNPs
Crystalline size of AgNPs calculated using Debye–Scherrer’s equation
| 2θ (deg) | θ | Planes-hkl | FWHM (deg) | Crystalline size (nm) | Average crystalline size (nm) |
|---|---|---|---|---|---|
| 38 | 19 | 111 | 0.041 | 35.70 | 36.01 ± 1.4 |
| 44 | 22 | 200 | 0.043 | 34.76 | |
| 64 | 32 | 220 | 0.047 | 34.77 | |
| 77 | 38.5 | 311 | 0.048 | 36.89 | |
| 81 | 40.5 | 222 | 0.048 | 37.97 |
Antimicrobial activity of colloidal AgNPs against various species of pathogenic bacteria, yeast and molds
| Sr. no. | Microorganisms | ZOI of 20 μl of AgNPs (mm) (y) | ZOI of 20 μl of 1 mM AgNO3 (mm) (x) | ZOI of 20 μl of H2O (mm) | Increase in the ZOI area (%)a |
|---|---|---|---|---|---|
| 1 |
| 12.66 ± 0.28 | 11.00 ± 0.0 | 0 ± 0 | 32.45 |
| 2 |
| 14.33 ± 0.57 | 13.16 ± 0.28 | 0 ± 0 | 18.57 |
| 3 |
| 14.16 ± 0.28 | 13.0 ± 0.5 | 0 ± 0 | 18.64 |
| 4 |
| 14.00 ± 0.5 | 12.33 ± 0.28 | 0 ± 0 | 28.92 |
| 5 |
| 15.0 ± 0.0 | 13.16 ± 0.28 | 0 ± 0 | 29.91 |
| 6 |
| 15.5 ± 0.5 | 13.5 ± 0.5 | 0 ± 0 | 31.82 |
| 7 |
| 12.50 ± 0.5 | 11.16 ± 0.28 | 0 ± 0 | 25.45 |
| 8 |
| 15.33 ± 0.28 | 13.5 ± 0.5 | 0 ± 0 | 28.94 |
| 9 |
| 15.5 ± 1.0 | 14.0 ± 0.5 | 0 ± 0 | 22.57 |
| 10 |
| 16.0 ± 1.0 | 14.0 ± 0.5 | 0 ± 0 | 30.61 |
| 11 |
| 12.0 ± 0.0 | 11.16 ± 0.28 | 0 ± 0 | 15.62 |
| 12 |
| 13.16 ± 0.28 | 11.0 ± 0.5 | 0 ± 0 | 43.12 |
| 13 |
| 13.0 ± 0.5 | 11.33 ± 0.28 | 0 ± 0 | 31.65 |
| 14 |
| 14.0 ± 1.0 | 10.0 ± 0.5 | 0 ± 0 | 96.00 |
| 15 |
| 14.0 ± 1.0 | 12.5 ± 1.0 | 0 ± 0 | 25.44 |
All experiments were performed in triplicate
aThe mean surface area of the growth inhibition zone (mm2) was calculated for AgNPs and AgNO3 from the mean diameter. The percent of increases of inhibition zone area for the AgNPs against different microorganism were calculated as (y2−x2)/x2 × 100, where x and y are the inhibition zone for 20 μl of AgNO3 and 20 μl of AgNPs respectively
Antibiotic-resistance profile of MDR strains and AgNPs susceptibility test
| Bacteria | Tested antibiotics | Disk content (µg) | ZOI (mm) | Antibiotics susceptibility interpretationa |
|---|---|---|---|---|
| ESBL+ve | Nalidixic acid | 30 | 6.0 ± 0.50 | R |
| Doxycycline | 30 | 16.16 ± 0.28 | S | |
| Norfloxacin | 10 | 8.0 ± 0.50 | R | |
| Nitrofurantoin | 30 | 15.0 ± 0.50 | I | |
| Cefixime | 30 | 6.0 ± 0.50 | R | |
| Cefixime/clavulanate | 5/10 | 8.0 ± 0.50 | R | |
| Cefoperazone | 75 | 6.0 ± 0.0 | R | |
| Cefoperazone/tazobactam | 75/10 | 19.5 ± 1.0 | S | |
| Ceftazidime | 30 | 7.0 ± 1.0 | R | |
| Cetazidime/clavulanate | 30/10 | 14.0 ± 0.0 | I | |
| Chloramphenicol | 30 | 15.16 ± 0.28 | I | |
| Cefprozil | 30 | 6.5 ± 0.50 | R | |
| Cefepime | 30 | 10.5 ± 0.50 | R | |
| AgNPs | 2.16b | 10.5 ± 0.50 | – | |
| AgNO3 | 3.4 | 9.16 ± 0.28 | – | |
| Sterile H2O | 20 µl | 0 ± 0 | – | |
|
| Oxacillin | 1 | 6.66 ± 0.28 | R |
| Cefoxitin | 30 | 19.33 ± 0.57 | R | |
| AgNPs | 2.16b | 13.5 ± 0.5 | – | |
| AgNO3 | 3.4 | 11.0 ± 0.0 | – | |
| Sterile H2O | 20 µl | 0 ± 0 | – | |
|
| Teicoplanin | 30 | 10.0 ± 0.0 | R |
| AgNPs | 2.16b | 13.16 ± 0.28 | – | |
| AgNO3 | 3.4 | 11.0 ± 0.0 | – | |
| Sterile H2O | 20 µl | 0 ± 0 | – |
All experiments were performed in triplicate
R resistant, I intermediate, S susceptible
aThe antibiotics susceptibility interpretation was based on CLSI guideline-2016
b20 μl of 1 mM AgNO3 (MW 169.87) contains 3.4 μg AgNO3 and the percentage of silver is 63.5% in nanoparticles (i. e 2.16 μg)
Fig. 5Antimicrobial activity of AgNPs coated surgical suture against a ESBL positive E. coli, b S. aureus MRSA, c Teicoplanin resistant S. pneumoniae. Control: Sterile H2O treated suture tested against d ESBL positive E. coli (E) S. aureus MRSA f Teicoplanin resistant S. pneumoniae